Table 4.

The clinical baseline and CT manifestations from the last scan in patients with COVID-19 with incomplete absorption status after discharge.

	All (n = 67)	Parenchymal band (n = 23)	Opacification (n = 44)	p -value
Age	46.81 ± 13.66	45.39 ± 14.16	47.40 ± 13.62	0.551
Gender, male/female	37/30	8/15	29/15	0.030
Underlying comorbidity yes/no	20/47	3/20	17/27	0.058
Clinical group: non-severe/severe	49/18	17/6	32/12	1.000
Period between onset and the last follow-up CT scan, median (IQR), day	60.00 (48.50–87.00)	75.00 (55.00–168.00)	58.00 (46.25–77.00)	0.0027*
Pulmonary lobe involved
Right upper lobe	23 (34.3%)	3 (13.0%)	20 (46.5%)	0.014
Right middle lobe	23 (34.3%)	7 (30.4%)	16 (37.2%)	0.780
Right lower lobe	47 (70.2%)	13 (56.5%)	34 (79.1%)	0.101
Left upper lobe	25 (37.3%)	6 (26.1%)	19 (44.2%)	0.239
Left lower lobe	35 (52.2%)	13 (56.5%)	22 (51.2%)	0.875
Location of lesions
Subpleural	50 (74.6%)	18 (78.3%)	32 (74.4%)	0.843
Both	17 (25.4%)	5 (21.7%)	12 (27.9%)
The existence of opacification				/
GGO	/	/	37 (86.5%)
Mixed (Mainly GGO)	/	/	4 (9.3%)
Mixed (Mainly Consolidation)	/	/	2 (4.7%)
Consolidation	/	/	1 (2.3%)
Extent Score	/	/	2.66 ± 3.47	/
Halo Sign	1 (1.5%)	0 (0%)	1 (2.3%)	1.000*
Reverse Halo Sign	0 (0 %)	0 (0%)	0 (0%)	/
Reticular patterns	0 (0%)	0 (0%)	0 (0%)	/
Air Bronchogram	0 (0%)	0 (0 %)	0 (0%)	/
Bronchiolectasis	1 (1.5%)	0 (0%)	1 (2.3%)	1.000*
Vascular Enlargement	0 (0 %)	0 (0.00%)	0 (0%)	/
Crazy-paving sign	0 (0%)	0 (0%)	0 (0.00%)	/
Pleural thickening	1 (1.5%)	0 (0 %)	1 (2.3%)	1.000*
Pleural traction	0 (0%)	0 (0%)	0 (0%)	/
Pleural effusion	0 (0 %)	0 (0%)	0 (0%)	/
Mediastinal Lymphadenopathy	0 (0 %)	0 (0%)	0 (0%)	/

^*CT manifestations from the scan before discharge.

^†CT manifestations from the scan at the peak stage.

The p value in bold indicates that P is less than 0.05 and is statistically significant.